Friday, 06 Dec 2019

You are here

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

The World Health Organization recommends that infants be exclusively breastfed until the age of 6 months. The

Data was drawn from the Pregnancy-induced Amelioration of Rheumatoid Arthritis (PARA) study, a nationwide prospective cohort study (2002 to 2008). They followed 249 pregnancies through pregnancy and until 6 months postpartum. Data

Postpartum breastfeeding rates in RA patients (vs general population) were:

  • 4-6 weeks = 43% (gen. Population - 63%)
  • 12 weeks = 26%  (gen. Population - 46%)
  • 26 weeks= 9%  (gen. Population - 41%)

Breastfeeding by RA women was significantly lower than the general population (p < 0.001).

The main reason for women to discontinue breastfeeding was the restart of medication (n = 129, 57.8%). Nevertheless, more than 40% of these patients restarted medication that was considered compatible with breastfeeding.

This large prospective study of RA women shows that postpartum they are less likely to breastfeed and demonstrate earlier cessation compared with the general population.

Education and intervention strategies supporting RA patients who wish to breastfeed are needed.

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Smoking Cessation Lowers RA Disease Activity and CV Risks

A multinational cross-sectional cohort study suggests that smoking cessation in rheumatoid arthritis (RA) patients is associated with lower disease activity measures, improved lipid profiles and lower rates of cardiovascular (CV) events.

Apremilast Reduces Oral Ulcers in Behcet's Syndrome

A multinational trial finds a statistically significant number of patients with Behçet's syndrome showed a greater reduction in the number of oral ulcers with apremilast compared with placebo.

Systemic JIA-Associated Lung Disease

A disease you’ve never heard of is becoming increasingly common and carries a very poor prognosis. 

For me, one of most important aspects of attending the ACR Annual Meeting is to learn about conditions that I don’t know and that may afflict my patients when I return back home. This year’s meeting was no different.

Tapering Of Therapy In RA: Maybe Not So Aggressive Next Time

This ACR has seen some more great work on tapering of therapy in rheumatoid arthritis. It’s a hot topic and one which I get asked about all the time by my patients. Commonly when I start oral csDMARDs patients want to know how long they be will on therapy and that naturally leads to a discussion about what the plan will be in the future about tapering.

ACR 2019 - Report From Day 3 (Tuesday)

Here's my summary of key studies presented Tuesday. 

Tofacitinib in Polyarticular JIA